Theralink® Technologies Receives Final Medicare Reimbursement Rate Determination and PTAN Enrollment
Important Milestone Toward Enabling Increased Access and Insight for Patients With Advanced Breast Cancer Through Theralink’s Precision Oncology Test Golden, Colorado — November 14, 2022 — Theralink Technologies (OTC: THER) (“Theralink” or the “Company”), a precision oncology company with a novel phosphoprotein-based assay for advanced breast cancer, today announced that the Company has received the […]
Theralink® Technologies Appoints Dr. Mattia Cremona as its Director of its Biopharma Laboratory
Seasoned Cancer Research Fellow with specialized interest in Reverse Phase Protein Array Technology to bolster Theralink’s management team Golden, Colorado—November 7, 2022 — Theralink Technologies, Inc. (OTC: THER) (“Theralink” or the “Company”), a precision oncology company with a novel phosphoprotein-based assay for breast cancer, today announced that it has appointed Dr. Mattia Cremona as its Director […]
Vivacitas Oncology Presents for the Second Year in a row at the 2022 SAPA Conference
Somerset, NJ, USA, October 1, 2022 – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a privately-held oncology company focused on tough–to–treat cancers, presents on October 1st, 2022 at the 2022 Sino-American Pharmaceutical Professional Association (SAPA) Conference. The SAPA Annual Conference is a tremendous platform for participants to share knowledge and viewpoints on important issues and […]
Infusion 51a launched disruptive cancer awareness campaign with over 50 local students across the streets of Dubai
Based on the premise that “there is a person behind each diagnosis,” #FACESNOTNUMBERS is a campaign that seeks to humanize statistics by portraying the experiences of those affected by cancer in a unique way. Dateline: DUBAI, UAE – 15.08.2022: Statistically, one in every three people globally will at some point in their lifetime be diagnosed […]